Product image of Havrix (Hepatitis A Virus (Inactivated), Algeldrate) supplied by GNH India

Havrix

Active Ingredient:
Hepatitis A Virus (Inactivated), Algeldrate
Origin:
EU

Havrix (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix is an injectable vaccine containing inactivated hepatitis A virus (1440 ELU per 0.5 mL) and algeldrate as a stabilizer. It is supplied as a sterile solution for intramuscular administration and is marketed in the European Union for the prevention of hepatitis A infection.

Manufacturer / TM Owner

Glaxosmithkline, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Havrix is indicated for active immunisation against hepatitis A virus. It is used in the following situations:

  • Routine vaccination of children and adults in endemic areas
  • Pre‑travel protection for persons visiting regions with high hepatitis A prevalence
  • Post‑exposure prophylaxis when administered within two weeks of exposure
  • Vaccination of individuals with chronic liver disease to reduce severe outcomes
  • Immunisation of laboratory personnel handling hepatitis A specimens

Side Effects

Most recipients experience mild, transient reactions after Havrix injection. Serious adverse events are rare.

Common

  • Injection‑site pain or redness
  • Low‑grade fever
  • Headache
  • Fatigue or malaise
  • Muscle aches
  • Nausea

Serious

  • Severe allergic reaction (anaphylaxis)
  • Guillain‑Barré syndrome (very rare)
  • High fever persisting >48 hours
  • Persistent joint swelling
  • Neurological symptoms such as weakness or numbness

Precautions & Warnings

Before receiving Havrix, consider the following precautions:

  • Verify no severe allergy to any vaccine component, especially gelatin or latex.
  • Defer vaccination in individuals with moderate or severe acute illness.
  • Discuss vaccination with pregnant or breastfeeding persons; safety data are limited.
  • Assess immune status; immunocompromised patients may have reduced antibody response.
  • Review history of Guillain‑Barré syndrome, as recurrence is possible.
  • Ensure proper storage and handling to maintain vaccine potency.

Avoid Interactions

Havrix generally has a low potential for drug interactions, but consider these situations:

Avoid

  • Concurrent administration of live vaccines within 4 weeks, as immune response may be affected.
  • Use with systemic corticosteroids at immunosuppressive doses, which can diminish antibody production.

Use with caution

  • Antipyretics (e.g., acetaminophen, ibuprofen) may mask low‑grade fever after vaccination.
  • Immunoglobulin therapy given within 2 weeks before or after vaccination can interfere with immune response.
  • Blood products or plasma containing anti‑hepatitis A antibodies may reduce vaccine efficacy.

Frequently Asked Questions

The typical schedule consists of two doses administered intramuscularly, with the second dose given 6 to 12 months after the first. A rapid schedule of two doses 1 month apart may be used for travelers.

Yes, Havrix is approved for use in children aged 12 months and older for routine hepatitis A immunisation.

Immunity after the complete Havrix series generally persists for at least 20 years, and many recipients retain protective antibodies for life.

Safety data in pregnancy are limited; vaccination should be considered only if the benefit outweighs potential risks, such as travel to high‑risk areas.

Seek immediate medical attention; anaphylaxis requires prompt treatment with epinephrine and emergency care.

Havrix can be administered concomitantly with most non‑live vaccines, but live vaccines should be spaced at least 4 weeks apart.

Acetaminophen may reduce fever after vaccination but does not appear to significantly affect the immune response to Havrix.

Havrix should be stored in a refrigerator between 2 °C and 8 °C and protected from freezing.

All hepatitis A vaccines contain inactivated virus, but formulations differ in antigen content and stabilizers; Havrix uses 1440 ELU per 0.5 mL with algeldrate.

Yes, but they may develop a lower antibody response and should be monitored for adequate seroconversion.

A booster is not routinely required for most adults, but it may be considered for high‑risk groups or after significant waning of antibodies.

Avoid vigorous exercise at the injection site for 24 hours and do not receive live vaccines within 4 weeks of Havrix administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hepatitis A Virus (Inactivated), Algeldrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT